CD40-dependent Activation of Phosphatidylinositol
3-Kinase/Akt Pathway Mediates Endothelial Cell Survival and in
Vitro Angiogenesis*
Maria Chiara
Deregibus,
Stefano
Buttiglieri,
Simona
Russo,
Benedetta
Bussolati, and
Giovanni
Camussi
From the Cattedra di Nefrologia, Dipartimento di Medicina Interna,
Università di Torino, and Centro Ricerca Medicina Sperimentale
(CeRMS), Torino 10126, Italy
Received for publication, January 22, 2003, and in revised form, March 11, 2003
 |
ABSTRACT |
CD40 has been involved in tumor and inflammatory
neoangiogenesis. In this study we determined that stimulation of
endothelial CD40 with sCD154 induced resistance to apoptosis and
in vitro vessel-like formation by human microvascular
endothelial cells (HMEC). These effects were determined to be mediated
by CD40-dependent signaling because they were inhibited by
a soluble CD40-muIg fusion protein. Moreover, apoptosis of HMEC was
associated with an impairment of Akt phosphorylation, which was
restored by stimulation with sCD154. The anti-apoptotic effect as well
as in vitro vessel-like formation and Akt phosphorylation
were inhibited by treatment of HMEC with two unrelated pharmacological
inhibitors of phosphatidylinositol 3-kinase (PI3K), wortmannin and
LY294002. CD40 stimulation induced a rapid increase in Akt enzymatic
activity that was not prevented by cycloheximide, an inhibitor of
protein synthesis. The enhanced Akt activity induced by stimulation of
endothelial CD40 was temporarily correlated with the association of
CD40 with TRAF6, c-Cbl, and the p85 subunit of PI3K. Expression of
negative-dominant Akt inhibited the activation of endogenous Akt
through CD40 stimulation, despite the observation that
association of CD40 with TRAF6, c-Cbl, and PI3K was intact. The
defective activation of Akt abrogated not only the anti-apoptotic
effect of CD40 stimulation but also the proliferative response, the
enhanced motility, and the in vitro formation of
vessel-like tubular structures by CD40-stimulated HMEC. In
conclusion, these results suggest that endothelial CD40, through
activation of the PI3K/Akt signaling pathway, regulates cell survival,
proliferation, migration, and vessel-like structure formation, all
steps considered critical for angiogenesis.
 |
INTRODUCTION |
CD40 is a member of the tumor necrosis factor
(TNF)1 receptor
superfamily, which provides activation signals in antigen-presenting cells such as B cells, macrophages, and dendritic cells (1, 2). Among
the molecular mechanisms that link immunity to inflammation, the
interaction between CD40 and its counterreceptor CD154 has rapidly
emerged as a key system in the regulation of vascular pathophysiological processes such as atherogenesis (3, 4), tumor
neoangiogenesis (5, 6), and inflammation (2, 8). Under physiological
conditions, CD40 is expressed at low levels on endothelial cells but is
up-regulated in areas of inflammation (9). Ligation of endothelial CD40
by CD154, either expressed on activated monocytes or T cells (2) or
disgorged by platelets upon activation (10), induces production of
various inflammatory cytokines and chemokines, pro-coagulant activity,
adhesion molecules, metalloproteinases, and inflammatory mediators
(11-14). These mediators have been implicated in the development and
progression of atherosclerosis. In situ analysis of human
atherosclerotic lesions revealed the co-expression of CD154 and CD40 on
vascular endothelium and smooth muscle cells (15). Blockade of
CD40-CD154 interaction in atherosclerosis was found not only to
diminish the formation and progression of mouse atheroma but also to
foster changes in lesions associated with plaque destabilization (16,
17). Recently, it has also been shown that the engagement of CD40 on
endothelial cells by CD154 induces in vitro vessel-like
tubule formation and expression of matrix metalloproteinases, two
events involved in neovascularization (18). In vivo, the
stimulation of CD40 triggered neoangiogenesis in mice (6, 19).
Moreover, blockade of CD40-CD154 interaction prevented vascularization
and tumor growth in an experimental model of Kaposi's sarcoma (6).
CD40 signaling is initiated by receptor oligomerization upon binding
the trimeric ligand CD154 (20). CD40 signaling elicits different
outcomes in distinct cell types, ranging from proliferation, survival,
and differentiation to growth suppression and apoptosis (21, 22), and
implies a complex regulation of CD40 signal transduction (23). Indeed,
the CD40 cytoplasmic C terminus lacks intrinsic kinase activity and
adaptor proteins of the TNF receptor-associated factor (TRAF) family
appear to mediate the activation of the CD40 signaling cascade
(24-28). It has been recently found that CD40 mediated Akt activation
in dendritic and B cells (29). Several studies indicate that
Akt-dependent signaling plays a critical role in the
regulation of vascular homeostasis and angiogenesis (for review, see
Ref. 30). Various growth factors, including vascular endothelial growth
factor (VEGF) and angiopoietin-1 as well as mechanical stimuli,
activate Akt in endothelial cells. However, the effect of stimulation
of endothelial CD40 on the activation of Akt and the role of Akt in
CD40-induced angiogenesis are unknown.
The aim of the present study was to investigate whether Akt is directly
activated by the engagement of endothelial CD40 by its ligand CD154 and
whether Akt mediates biological effects relevant for CD40-induced
angiogenesis such as cell survival, proliferation, migration, and
vessel-like structure formation.
 |
EXPERIMENTAL PROCEDURES |
Reagents--
ECAF, DMEM, and
D-valine-modified DMEM, bovine serum albumin fraction V
(tested for not more than 1 ng of endotoxin per mg) were purchased from
Sigma Chemical Co. Modified MCDB131 medium was obtained from
Invitrogen, FCS was from EuroClone Ltd. (Wetherby West Yorkshire, UK).
Recombinant human soluble CD154 trimeric protein (sCD154), a
cross-linking Ab (enhancer), and CD40-muIg fusion protein, consisting
of the extracellular domain of human CD40 fused to mouse IgG2a, were
from Alexis Biochemicals (San Diego, CA).
Mouse monoclonal antibodies specific for TRAF2 (IgG1, H-10) and TRAF3
(IgG1, G-6), polyclonal rabbit anti-TRAF6 (H-274) IgG, polyclonal goat
antibody against human CD40, Akt, and phosphorylated Akt (P-Akt), and
isotypic control antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Mouse monoclonal anti-c-Cbl (IgG1) was
from BD Transduction Laboratories (San Diego, CA). The polyclonal
rabbit antiserum anti p85 subunit of PI3-K (P-85) and active Akt1 were
from Upstate Biotechnology (Lake Placid, NY).
Cell Cultures--
Microvascular endothelial cells (HMEC) were
obtained from derma using anti-CD31Ab coupled to magnetic beads, by
magnetic cell sorting using the MACS system (Miltenyi Biotec, Auburn,
CA). Primary cultures were grown in D-valine-substituted
DMEM to avoid fibroblast growth (Sigma).
HMEC were immortalized by infection of primary cultures with a
replication-defective adeno-5/SV40 virus as previously described (31).
HMEC were characterized as endothelial cells by morphology, positive
staining for vWF antigen, CD31, CD105, and the fucosylated receptors
for plant lectins (Ulex europeus I and Bandeira Simplicifolia). Cytoplasmic staining was positive for vimentin and negative for cytokeratin and desmin, as previously described (31). HMEC were cultured on ECAF (Sigma)-coated tissue culture plates in modified MCDB131 medium (Invitrogen) supplemented with epidermal growth factor
(10 ng/ml), hydrocortisone (1 µg/ml), bovine brain extract (all from
Biowittaker, Walkersville, MD) and 20% FCS.
HMEC Transfection--
To obtain HMEC expressing the
negative-dominant Akt (ND-Akt), HMEC were transfected with cDNA of
K179M Akt1 mutant containing a Myc-His tag at the 3'-end of the Akt1
open reading frame and a substitution of methionine for lysine at
residue 179 in pUSEamp plasmid (Upstate Biotechnology). As control
cells were transfected with the empty plasmid (WT-Akt). HMEC seeded in
60-mm Petri dishes at a density of 5 × 106 cells per
dish in DMEM containing 10% FCS, without antibiotics were transfected
using 8 µg/ml DNA and 20 µl of LipofectAMINE 2000 (Invitrogen)
according to the protocol suggested by the manufacturer. Transfected
cells were stably selected by culturing in the presence of 1 mg/ml
geneticin (G418, Sigma). Successful transfection was evaluated by
positive immunofluorescence for anti-HIS (C-terminal) antibody
(Invitrogen). HMEC were stably transfected up to the 10th passage.
Experiments were performed at the 6th-7th passage.
Cytofluorimetric Analysis--
For cytofluorimetric analysis,
cells were kept for 24 h in DMEM with 10% FCS in the absence of
growth factors. Cells were detached from plates with non-enzymatic cell
dissociation solution, washed in PBS containing 2% heat-inactivated
human serum, and incubated for another 15 min with whole
heat-inactivated human serum to block remaining nonspecific sites.
Cells were then incubated for 30 min at 4 °C with the appropriate Ab
or with the irrelevant control in PBS containing 2% heat-inactivated
human serum. The intracellular staining for vimentin, desmin,
cytocheratin, and vWF was evaluated in permeabilized cells. Cells
(2 × 106) were fixed in 1% paraformaldehyde at
4 °C for 20 min and with the appropriate Ab at 4 °C for 45 min in
permeabilizing solution (PBS containing 0.1% saponin, 1% bovine serum
albumin, and 0.1% sodium azide). When needing a second-step reagent,
cells were stained with fluorescein isothiocyanate-conjugated goat
anti-mouse or -rabbit IgG and incubated for another 30 min at 4 °C.
Cells were analyzed by FACS (BD Biosciences, Mountain View, CA). 10,000 cells were analyzed for each experimental point.
Assessment of Apoptosis--
Apoptosis was evaluated using TUNEL
assay analysis (ApopTag Oncor, Gaithersburg, MD). After serum
withdrawal or treatment with 0.25 µg/ml vincristine for 24 h in
the presence or absence of sCD154 (100 ng/ml) and the enhancer
cross-linking antibody (1 µg/ml), cells were suspended in PBS, fixed
in 1% paraformaldehyde in PBS, pH 7.4, for 15 min at 4 °C, and then
in precooled ethanol/acetic acid (2:1) for 5 min at
20 °C. Cells
were treated with terminal deoxynucleotidyl transferase (TdT) enzyme,
incubated in an humidified chamber at 37 °C for 1 h, and then
with warmed fluorescein isothiocyanate-conjugated anti-digoxigenin for
30 min at room temperature. After washing, samples were mounted in
medium containing 1 µg/ml of propidium iodide and the cells
analyzed by immunofluorescence.
DNA Fragmentation--
Apoptosis is accompanied by
fragmentation of DNA (32). To determine the occurrence of DNA
fragmentation, total DNA was extracted from unstimulated and stimulated
HMEC as previously described (33). The culture medium was removed and
centrifuged at 3000 × g for 5 min to collect detached
cells. Adherent cells were lysed with a hypotonic lysis buffer (10 mM Tris-HCl, pH 8, containing EDTA (10 mM) and
Triton X-100 (0.5%)) and then pooled with pellets made of detached
cells. RNA and proteins were digested using 0.1 mg/ml RNase at 37 °C
for 1 h, followed by proteinase K treatment for 2 h at
50 °C. DNA was homogenized by TRI (Sigma) reagent for 10 min at room
temperature. After centrifugation, the aqueous phase was gently
removed, and the DNA pellet was resuspended with 100% ethanol and
centrifuged at 6000 rpm for 5 min at 4 °C. The ethanol was removed,
and the DNA pellet was washed twice with a solution containing 0.1 M sodium citrate in 10% ethanol for 30 min at room
temperature under agitation and centrifuged at 6000 × g for 5 min at 4 °C. Next, the DNA pellet was suspended in 75% ethanol, shaken for 15 min at room temperature, and centrifuged at 6000 × g for 5 min at 4 °C. The ethanol was
removed, and the DNA pellet was briefly air-dried at room temperature.
The DNA pellet was dissolved in 8 mM NaOH by slowly passing
through a pipette and centrifuged at 10,800 rpm for 10 min at 4 °C.
The supernatant was collected and resolved on a 2% agarose gel,
stained with 0.5 mg/ml ethidium bromide.
Cell Proliferation Assay--
Cells were seeded at 8000 cells/well into 96-well plates in DMEM medium containing 10% FCS and
left to adhere. DNA synthesis was detected as incorporation of
5-bromo-2'-deoxyuridine (BrdUrd) into the cellular DNA using an ELISA
kit (Roche Applied Science), following the manufacturer's
instructions. Briefly, after washing, cells were added with 10 µM BrdUrd, incubated in DMEM without FCS, and stimulated
or not with sCD154 (100 ng/ml of sCD154 and 1 µg/ml enhancer
cross-linking Ab) or in DMEM plus 10% FCS for 18 h. Cells were
then fixed with 0.5 M ethanol/HCl and incubated with
nuclease to digest the DNA. BrdUrd incorporated into the DNA was
detected using an anti-BrdUrd peroxidase-conjugated mAb and visualized
with a soluble chromogenic substrate. Optical density was measured with
an ELISA reader at 405 nm.
In Vitro Cell Migration--
A total of 1 × 105 cells/well were plated and rested for 12 h in DMEM
containing 1% FCS, then washed three times with phosphate-buffered saline, and incubated with DMEM containing 0.25% bovine serum albumin
in the presence or absence of sCD154 (100 ng/ml) and the enhancer, a
cross-linking Ab (1 µg/ml). Cell division did not start to any
significant degree during the experiments. Cell migration was studied
over a 4-h period under a Nikon Diaphot-inverted microscope with a ×20
phase-contrast objective in an attached, hermetically sealed plexiglas
Nikon NP-2 incubator at 37 °C (6). Cell migration was recorded using
a JVC-1CCD video camera. Image analysis was performed with a MicroImage
analysis system (Casti Imaging srl, Venice, Italy) and an
IBM-compatible system equipped with a video card (Targa 2000;
Truevision, Santa Clara, CA). Image analysis was performed by digital
saving of images at 15-min intervals. Migration tracks were generated
by marking the position of the nucleus of individual cells on each
image. The net migratory speed (velocity straight line) was calculated
with MicroImage software based on the straight line distance between
the start and end points divided by the time of observation (6).
Migration of at least 30 cells was analyzed for each experimental
condition. Values are given as means ± 1 S.D.
In Vitro Tube Formation--
In vitro formation of
tubular structures (34) was studied on growth factor-reduced Matrigel
diluted 1:1 in ice with cold DMEM. To evaluate the endothelial tube
formation, HMEC were washed twice with phosphate-buffered saline,
detached with 1% trypsin, and seeded (5 × 104
cells/well) onto Matrigel-coated wells in DMEM containing 0.25% bovine
serum albumin in the presence or absence of sCD154 (100 ng/ml) and the
enhancer, a cross-linking Ab (1 µg/ml). Cells were periodically
observed with a Nikon-inverted microscope, and experimental results
were recorded at different times. Image analysis was performed with the
MicroImage analysis system (Casti Imaging srl).
Akt Kinase Assay--
To assay for Akt kinase activity, cells
were serum-starved, submitted to different experimental conditions,
washed twice in cold phosphate-buffered saline, and lysed in ice with
900 µl of lysis buffer containing 1% Triton X-100, 10% glycerol,
137 mM NaCl, 20 mM Tris-HCl (pH 7.5), 2 µg/ml
aprotinin, 2 µg/ml leupeptin, 1 mM phenylmethylsulfonyl
fluoride, 20 mM NaF, 1 mM
Na2PPi, and 1 mM
Na3VO4 as previously described (33). Equal
amounts of lysates (300 µg) were precleared by centrifugation and
preabsorbed with protein A-protein G (1:1) agarose slurry.
Immunoprecipitation was carried out for 18 h using the immobilized
anti-Akt1G1 mAb (Cell Signaling Technology) cross-linked to agarose.
Immunoprecipitates were washed three times with lysis buffer and twice
with Akt kinase buffer (20 mM HEPES, pH 7.4, 10 mM MgCl2, 10 mM MnCl2).
Kinase assays were performed for 30 min at 30 °C under continuous
agitation in kinase buffer containing 200 µM ATP, 1 µg
of GSK-3 fusion protein, according to the manufacturer's instructions
for the non-radioactive Akt kinase assay (Cell Signaling Technology).
Samples were analyzed by Western blot analysis using 12%
SDS-polyacrylamide gel and anti-HRP conjugated anti-rabbit Ab and
HRP-conjugated anti-biotin Ab (Cell Signaling Technology). Data for the
kinase activity are expressed as fold induction with respect to the
activity exhibited by control HMEC. In parallel, to assess the level of
expression of Akt, the same amounts of immunoprecipitates were
submitted by Western blot, using polyclonal goat antibody against human Akt (1 µg/ml) as previously described (33).
Immunoprecipitation and Western Blot Analysis--
HMEC cells
were lysed at 4 °C for 1 h in a lysis buffer (50 mM
Tris-HCl, pH 8.3, containing 1% Triton X-100, 1 mM
phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, and 100 units/ml
aprotinin) and centrifuged at 15,000 × g.
Immunoprecipitation with anti-CD40 polyclonal goat IgG cross-linked to
Sepharose-protein A was performed as described (33, 35). The protein
contents of the supernatants and of the immunoprecipitates were
measured by the Bradford method. Aliquots containing 30 µg of protein
per lane of the immunoprecipitates or of the cell lysates were
subjected to 10% SDS-PAGE under reducing conditions and electroblotted
onto nitrocellulose membrane filters. The blots were blocked with 5%
nonfat milk in 20 mM Tris-HCl, pH 7.5, 500 mM
NaCl plus 0.1% Tween (TBS-T). The membranes were subsequently
immunoblotted overnight at 4 °C with the relevant primary antibodies
or the irrelevant isotypic controls at the appropriate concentration.
After extensive washing with TBS-T, the blots were incubated for 1 h at room temperature with peroxidase-conjugated isotype-specific
secondary antibodies (Santa Cruz Biotechnology), washed with TBS-T,
developed with ECL detection reagents (Amersham Biosciences) for 1 min,
and exposed to X-Omat film (Eastman Kodak Co., Rochester, NY).
 |
RESULTS |
HMEC expressed CD40, as evaluated by cytofluorimetric analysis
(Fig. 1A). TUNEL assay showed
a marked increase in HMEC apoptosis after 24 h of starving,
without FCS or treatment with 0.25 µg/ml of vincristine (Fig.
1B). Stimulation of CD40 with sCD154 prevented apoptosis
induced both by serum deprivation or treatment with vincristine.
Soluble CD40-muIg fusion protein inhibited the anti-apoptotic effect
elicited by sCD154, preventing the interaction between sCD154 and the
CD40 expressed by HMEC (Fig. 1B). This result suggests that
the anti-apoptotic effect of sCD154 was mediated by the
CD40-dependent signaling. Treatment of HMEC with two
unrelated PI3K pharmacological inhibitors, wortmannin (0.1 µM) and LY294002 (10 µM) abrogated the
anti-apoptotic effect of sCD154, suggesting that this effect was
dependent on the activation of PI3K. Wortmannin and LY294002 also
inhibited the sCD154-induced in vitro cell motility (Fig. 2). The tube formation in Matrigel was
absent in unstimulated HMEC cells (Fig.
3A). As shown in Fig.
3B, sCD154 induced a rapid formation of vessel-like tubular
structures of endothelial cells. Soluble CD40-muIg fusion protein
inhibited vessel-like formation elicited by sCD154 (not shown). The
sCD154-induced in vitro vessel-like formation was
significantly reduced by treatment with wortmannin and LY294002 (Fig.
3, C and D).

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 1.
Expression of CD40 by HMEC and effect of CD40
stimulation on HMEC apoptosis. Panel A,
cytofluorimetric analysis of CD40 expression by HMEC. The figure is
representative of three individual experiments. In each experiment the
Kolmogorov-Smirnov statistical analysis between anti-CD40 IgG2a mAb
(solid line) and the isotypic control (dotted
line) was significant (p < 0.05). Panel
B, apoptosis was evaluated by TUNEL assay as percentage of
apoptotic cells after 24-hour serum withdrawal (noFCS) or
treatment with 0.25 µg/ml vincristine. Where indicated, cells were
stimulated with 100 ng/ml of sCD154 (plus 1 µg/ml enhancer) alone or
in the presence of 20 ng/ml CD40-muIg fusion protein
(CD40FP) or of 0.1 µM wortmannin or 10 µM LY294002. As control, cells were incubated in the
presence of 10% FCS or with FCS plus 0.1 µM wortmannin
or plus 10 µM LY294002. Data are expressed as mean ± 1 S.D. from three different experiments.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 2.
Effect of PI3K pharmacological inhibitors on
sCD154-induced motility of HMEC. Time course of HMEC motility
(1 × 105 cells) induced by sCD154 (100 ng/ml, plus 1 µg/ml enhancer) in the presence or absence of 0.1 µM
wortmannin or 10 µM LY294002. Motility was measured by
time-lapse cinematography and digital image analysis as described under
"Experimental Procedures." As control, HMEC were incubated with
vehicle alone. Results are expressed as means ± 1 S.D. from three
individual experiments. Analysis of variance with Newmann-Keul's
multicomparison test was performed for sCD154 versus control
or for sCD154 versus sCD154 + wortmannin or sCD154 + LY294002. *, p < 0.05.
|
|

View larger version (140K):
[in this window]
[in a new window]
|
Fig. 3.
Micrographs representative of in
vitro formation of vessel-like structures by HMEC after CD40
stimulation. Tube formation by HMEC (5 × 104
cells) plated on growth factor reduced Matrigel (see "Experimental
Procedures") was evaluated after stimulation of HMEC for 5 h at
37 °C with vehicle alone (A), sCD154 (100 ng/ml, plus 1 µg/ml enhancer) (B), or sCD154 (100 ng/ml, plus 1 µg/ml
enhancer) in the presence of 0.1 µM wortmannin
(C) or 10 µM LY294002 (D). ND-Akt
HMEC were stimulated with vehicle alone (E) or sCD154
(F). Magnification: ×120.
|
|
Apoptosis of HMEC induced by serum deprivation and treatment with
vincristine was associated with an impairment of Akt phosphorylation (P-Akt) that was restored by treatment with sCD154 (Fig.
4). This effect was dependent on CD40
stimulation since it was inhibited by the soluble CD40-muIg fusion
protein. When PI3K was inhibited by wortmannin and LY294002, the
CD40-induced phosphorylation of Akt was significantly prevented.

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 4.
Effect of treatment with sCD154 and PI3K
pharmacological inhibitors on Akt phosphorylation in HMEC. Cell
lysates (30 µg of protein) were immunoblotted with anti-P-Akt, -Akt,
or - -actin antibodies. Panel A, densitometric analysis
and panel B, representative immunoblot of P-Akt expression
(panel A, black column) and Akt expression
(panel A, open column). Row 1, control
HMEC cultured in DMEM containing 10% FCS; row 2, HMEC serum
starved for 24 h; row 3, HMEC serum-starved treated
with sCD154 (100 ng/ml, plus 1 µg/ml enhancer); row 4,
HMEC serum-starved treated with sCD154 and 20 ng/ml CD40-muIg fusion
protein; row 5, HMEC treated with 0.25 µg/ml vincristine;
row 6, HMEC treated with 0.25 µg/ml vincristine plus
sCD154 (100 ng/ml, plus 1 µg/ml enhancer); row 7, HMEC
treated with 0.25 µg/ml vincristine plus sCD154 (100 ng/ml, plus 1 µg/ml enhancer) and 20 ng/ml CD40-muIg fusion protein; row
8, HMEC treated with 0.25 µg/ml vincristine plus sCD154 (100 ng/ml, plus 1 µg/ml enhancer) and 0.1 µM wortmannin;
row 9, HMEC treated with 0.25 µg/ml vincristine plus
sCD154 (100 ng/ml, plus 1 µg/ml enhancer) and 10 µM
LY294002. Panel A, data are expressed as mean ± 1 S.D.
from three different experiments.
|
|
To evaluate whether Akt enzymatic activity was directly induced by CD40
stimulation, Akt activity was measured in HMEC following incubation
with sCD154 for different times. As shown in Fig.
5, A and B, sCD154
induced a rapid and sustained enhancement of Akt enzymatic activity.
This Akt activation was not inhibited by cycloheximide, an inhibitor of
protein synthesis, suggesting that a CD40-induced synthesis of
secondary mediators is not critical for Akt activation (not shown). It
is known that TNF receptor family members, including CD40, transduce
signals through TRAF family proteins. In particular an interaction
between TRAF6, c-Cbl protein, and PI3K in dendritic cells (29) has been
shown. In the present study we evaluated whether endothelial CD40 after
stimulation with sCD154 associates TRAF family proteins, c-Cbl, and the
p85 subunit of PI3K. Immunoprecipitation of CD40 followed by Western
blotting showed that stimulation of endothelial CD40 induced rapid
association of TRAF2 and 6, c-Cbl, and the p85 PI3K subunit (Fig.
5C). Such association was temporarily correlated with
enhanced Akt activity (Fig. 5A). The association of TRAF3 to
CD40 was minimal (Fig. 5C).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 5.
Time course of Akt kinase activity and
association of PI3K, c-Cbl, and TRAFs with CD40 upon sCD154 stimulation
of HMEC. HMEC were treated for the indicated times with sCD154
(100 ng/ml, plus 1 µg/ml enhancer) and lysed. As control
(Ctrl), cells were treated with vehicle alone. Kinase
reactions and Western blot analysis were performed in anti-Akt
immunoprecipitates from the corresponding lysates, as described under
"Experimental Procedures." Akt activity was assessed using
GSK-3 / as substrate for phosphorylation (P-GSK-3 / ).
A, densitometric analysis of Akt kinase activity expressed
as fold increase with respect to unstimulated cells (mean ± 1 S.D. from three different experiments). B, representative
Western blot analysis showing P-GSK-3 / generation and specific
bands detected by the anti-Akt antibody. C, after treatment
of HMEC with sCD154 (100 ng/ml, plus 1 µg/ml enhancer) for the
indicated times, CD40 was immunoprecipitated from cell lysates. The
immunoprecipitates were probed with antibodies to PI3K, c-Cbl, TRAF2,
TRAF6, and TRAF3. Data are representative from three independent
experiments.
|
|
In order to evaluate the relevance of Akt in the biological activities
elicited by CD40 stimulation in HMEC, we developed negative-dominant
HMEC for Akt by transfecting the cells with Akt1 cDNA containing
the mutation of lysine 179 to methionine. Expression of ND-Akt has been
shown to interfere with the activation of endogenous Akt1 (36, 37).
Fig. 6 (A and B)
compares Akt activity after CD40 stimulation with sCD154 in ND-Akt and
in WT-Akt HMEC, transfected with an empty vector as control. At
variance with the WT-Akt HMEC, ND-Akt HMEC did not display enhancement of Akt activity, despite the observation that the pathway of
CD40-dependent PI3K activation was intact. Indeed, no
differences in the association of CD40 with TRAF6, c-Cbl, and PI3K was
observed after stimulation with sCD154 (Fig. 6C). As shown
in Fig. 7, the anti-apoptotic effect of
CD40 stimulation was abrogated in ND-Akt but not in WT-Akt HMEC. ND-Akt
showed an enhanced apoptosis also in basal conditions. In
addition, the proliferative response of HMEC to CD40 stimulation
observed in WT-Akt, was impaired in ND-Akt cells (Fig.
8A). Moreover, the in
vitro formation of vessel-like tubular structures by
CD40-stimulated HMEC plated on Matrigel was reduced in ND-Akt cells
(Fig. 3, E and F), suggesting a role of Akt
activation in the coordinate migration of endothelial cells. Indeed, as
shown by the time-lapse analysis of HMEC motility, WT-Akt exhibited an
enhanced motility after stimulation with sCD154 compared with control
whereas ND-Akt did not (Fig. 8B and Fig.
9).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 6.
Comparison of Akt kinase activity and
association of PI3K, c-Cbl, and TRAF-6 with CD40 upon sCD154
stimulation in ND-Akt and WT-Akt HMEC. Akt-negative-dominant HMEC
were generated by transfecting the cells with Akt1 cDNA containing
the mutation of lysine 179 to methionine. Control WT-Akt were
transfected with the empty vector. ND-Akt and WT-Akt HMEC were treated
for the indicated times with sCD154 (100 ng/ml, plus 1 µg/ml
enhancer) and lysed. Kinase reactions and Western blot analysis were
performed in anti-Akt immunoprecipitates from the corresponding
lysates, as described under "Experimental Procedures."
A, densitometric analysis of Akt kinase activity was
expressed as fold increase with respect to unstimulated cells
(mean ± 1 S.D. from three different experiments). ND-Akt,
dark column; WT-Akt, open column. B,
representative Western blot showing P-GSK-3 / generation and
specific bands detected by the anti-Akt antibody in ND-Akt and WT-Akt
HMEC. C, after treatment of ND-HMEC with sCD154 (100 ng/ml,
plus 1 µg/ml enhancer) for the indicated times, CD40 was
immunoprecipitated from cell lysates, and the immunoprecipitates were
probed with antibodies to PI3K, c-Cbl, and TRAF6. Data are
representative of three independent experiments.
|
|

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 7.
Abrogation of anti-apoptotic effect of CD40
stimulation in ND-Akt HMEC. A, DNA fragmentation was
detected after DNA extraction and electrophoresis on 2% agarose gel.
Row 1, control WT-Akt HMEC cultured in DMEM containing 10%
FCS; row 2, WT-Akt HMEC serum-starved for 24 h;
row 3, WT-Akt HMEC serum-starved treated with sCD154 (100 ng/ml, plus 1 µg/ml enhancer); row 4, control ND-Akt HMEC
cultured in DMEM containing 10% FCS; row 5, ND-Akt HMEC
serum-starved for 24 h; row 6, ND-Akt HMEC
serum-starved treated with sCD154 (100 ng/ml, plus 1 µg/ml enhancer).
B, apoptosis of HMEC evaluated by TUNEL assay after 24 h incubation with different stimuli (see "Experimental
Procedures"). ND-Akt (dark column) and WT-Akt (open
column) HMEC were incubated with 10% FCS, without FCS
(noFCS), without FCS plus sCD154 (100 ng/ml, plus 1 µg/ml
enhancer) or with 0.25 µg/ml vincristine or 0.25 µg/ml vincristine
plus sCD154 (100 ng/ml, plus 1 µg/ml enhancer). Data are expressed as
mean ± 1 S.D. from three different experiments.
|
|

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 8.
Reduction of proliferation and motility
induced by CD40 stimulation in ND-Akt HMEC. A,
proliferation was evaluated by BrdUrd incorporation in ND-Akt and
WT-Akt HMEC after 18-hour stimulation with vehicle alone or sCD154 (100 ng/ml, plus 1 µg/ml enhancer). OD, optical density.
Panel B, cell motility, measured by time-lapse
cinematography and digital image analysis, was evaluated after 4 h
of stimulation with vehicle alone or sCD154 (100 ng/ml, plus 1 µg/ml
enhancer) in ND-Akt and WT-Akt HMEC. Data are expressed as mean ± 1 S.D. from three different experiments.
|
|

View larger version (79K):
[in this window]
[in a new window]
|
Fig. 9.
Micrographs representative of time-lapse
analysis of WT-Akt and NT-Akt HMEC motility after stimulation with
sCD154. Motility was performed by digital saving at 15-min
intervals. Migration tracks (magnification: ×120) were generated by
marking the position of the nucleus of individual cells in each image
(see "Experimental Procedures"). WT-Akt (A and
B) and ND-Akt (C and D) HMEC were
stimulated for 4 h at 37 °C with vehicle alone (A
and C) or with sCD154 (100 ng/ml, plus 1 µg/ml enhancer)
(B and D).
|
|
 |
DISCUSSION |
In the present study we demonstrated that resistance to apoptosis
and the in vitro vessel-like formation elicited in
endothelial cells after CD40 stimulation were dependent on the
activation of Akt. This activation was triggered by PI3K that
associated with CD40 after its ligation by sCD154.
The stimulation of endothelial CD40 plays an important role in the
phenotypic modulation of the endothelium to an activated state (10).
CD40 was shown to induce expression of collagenase and stromelysin on
human monocytes/macrophages, and of collagenase, stromelysin,
gelatinase B, and activated gelatinase A on vascular smooth muscle and
endothelial cells (11-14). Ligation of endothelial CD40 by CD154,
either expressed on activated monocytes or T cells or disgorged from
platelet granules after activation, stimulated the production of
various inflammatory cytokines by endothelial cells (11, 13). Moreover,
it has been reported that surface-expressed CD154 is rapidly cleaved
with generation of a circulating soluble CD154, which remains trimeric
and biologically active (10). A soluble form of CD154 released from the
surface of tumor cells (38) may contribute to endothelial activation in
tumor angiogenesis. In vivo stimulation of endothelial CD40
was shown to trigger neoangiogenesis and its inhibition limited
neoangiogenesis and allowed apoptotic regression in an experimental
model of tumor neoangiogenesis (6).
In the present study we found that stimulation of endothelial CD40 with
sCD154 prevented apoptosis induced both by serum deprivation or
treatment with vincristine and induced motility and vessel-like formation by HMEC. These effects were mediated by
CD40-dependent signaling because it was abrogated by
preventing the interaction between sCD154 and CD40 by a soluble
CD40-muIg fusion protein. In addition, we found that apoptosis of HMEC
was associated with an impairment of Akt phosphorylation, which was
restored by sCD154. The anti-apoptotic effect of sCD154 as well as cell
motility, vessel-like formation, and Akt phosphorylation
were inhibited by treatment of HMEC with two unrelated pharmacological
inhibitors of PI3K, wortmannin and LY294002, suggesting that the effect
was dependent on the activation of this kinase.
PI3K/Akt is one of the central pathways involved in survival signaling
(39). Several receptors, including those for VEGF (40), IGF-1 (41), and
IL-3 (42), transmit survival signals through these pathways. PI3K
activation catalyzes the transfer of a phosphate group from ATP to the
D3 position of phosphatidylinositol (PI), thus generating
3'-phosphatidylinositol phosphates (43). 3'-Phosphatidylinositol
phosphates serve as binding sites for proteins that possess a
pleckstrin homology domain such as Akt. The binding of Akt to
3'-phosphatidylinositol phosphates results in its translocation
from cytosol to plasma membrane and phosphorylation of threonine 308 and serine 473 residues. Phosphorylation of threonine 308 and membrane
localization depend on the activation of a
phosphatidylinositol-dependent kinase-1 that also contains
a pleckstrin homology domain (44). Several studies have shown that Akt
is the major effector of PI3K survival signaling (39, 45, 46).
In the present study we found that a rapid increase in Akt enzymatic
activity was induced by CD40 stimulation. Although, CD40 is known to
stimulate the synthesis of cytokines that may activate Akt (19), we
found that Akt activation was rapid and independent from protein
synthesis, suggesting a direct effect of CD40 stimulation.
CD40 is a member of the TNF receptor family, which lacks intrinsic
enzymatic activity but is linked to intracellular signaling cascades
through TRAF proteins (24-28). Activation of
CD40-dependent signaling pathways is thought to be mediated
primarily by recruitment of several members of the TRAF protein family
to the multimerized CD40 cytoplasmic domain (23). The CD40 cytoplasmic
domain contains a membrane-proximal site that binds TRAF6 and a
membrane-distal site that binds TRAF1, TRAF2, and TRAF3 (24, 25). We
found that TRAF6 and TRAF2 co-precipitated with CD40 after stimulation of HMEC with sCD154. No significant enhancement of TRAF3 binding to
CD40 was observed after sCD154 stimulation of endothelial cells. It has
been described that TRAF3 up-regulation by shear stress abrogates CD40
signaling in endothelial cells (47). In contrast, the binding of
CD40-TRAF2 domain has been associated with the activation of
transcription factors and of apoptosis-regulating proteins (7, 48-52).
Recently it has been found that in dendritic cells TRAF6 in concert
with c-Cbl mediates the binding and the activation of PI3K by TNF
receptor family members (29). In the present study we found that the
enhanced Akt activity induced by stimulation of endothelial CD40 was
temporarily correlated with the association of CD40 with TRAF6, c-Cbl,
and the p85 subunit of PI3K. c-Cbl, a cytoplasmic adapter molecule
implicated in the negative regulation of signaling from a variety of
tyrosine kinase receptors, has been recently identified as a positive
modulator of the TNF receptor superfamily (29). Information on the
critical role of c-Cbl in the interaction of PI3K and in the subsequent activation of Akt was obtained in c-Cbl negative-dominant B cells (29).
In this context, it has been proposed that c-Cbl recruited PI3K by
favoring association with TRAF6.
In order to evaluate the relevance of Akt activation to biological
activity dependent on the stimulation of endothelial CD40, we developed
Akt negative-dominant cells by transfecting HMEC with Akt1 cDNA
containing the mutation of lysine 179 to methionine (37). Expression of
ND-Akt has been shown to interfere with activation of the endogenous
Akt1, suggesting that it displaced endogenous Akt from critical
protein-protein interactions (36, 37). CD40 stimulation in ND-Akt HMEC
failed to enhance Akt activity, despite the observation that the
association of CD40 with TRAF6, c-Cbl, and PI3K was intact. The
defective activation of Akt abrogated not only the anti-apoptotic
effect of CD40 stimulation but also the proliferative response, the
in vitro formation of vessel-like tubular structures, and
the enhanced motility of HMEC.
In conclusion, these results suggest that the PI3K/Akt signaling axis
was activated by endothelial CD40 stimulation and regulated multiple
critical steps in angiogenesis, including endothelial cell survival,
proliferation, migration, and vessel-like structure formation.
 |
FOOTNOTES |
*
This work was supported by the Associazione Italiana per la
Ricerca sul Cancro (AIRC), by Istituto Superiore di Sanità
(Targeted Project AIDS), by Italian Ministry of University and Research (MIUR) FIRB project (RBNE01HRS5-001) and COFIN 01, by Italian Ministry
of Health (Ricerca Finalizzata 02), and by the special project
Oncology, Compagnia San Paolo/FIRMS.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Cattedra di
Nefrologia, Dipartimento di Medicina Interna, Ospedale Maggiore S. Giovanni Battista, Corso Dogliotti 14, 10126, Torino, Italy. Tel.: 39-011-6336708; Fax: 39-011-6631184; E-mail:
giovanni.camussi@unito.it.
Published, JBC Papers in Press, March 12, 2003, DOI 10.1074/jbc.M300711200
 |
ABBREVIATIONS |
The abbreviations used are:
TNF, tumor necrosis
factor;
TRAF, TNF receptor-associated factor;
DMEM, Dulbecco's
modified Eagle's medium;
FCS, fetal calf serum;
WT, wild type;
HMEC, human microvascular endothelial cells;
TUNEL, terminal
deoxynucleotidyltransferase-mediated dUTP nick end-labeling;
Ab, antibody;
PI3K, phosphatidylinositol 3-kinase;
ND, negative-dominant;
ELISA, enzyme-linked immunosorbent assay;
FACS, fluorescence-activated
cell sorter;
HRP, horseradish peroxidase.
 |
REFERENCES |
1.
|
Clark, E. A.,
and Ledbetter, J. A.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
4494-4498[Abstract]
|
2.
|
Grewal, I. S.,
and Flavell, R. A.
(1998)
Annu. Rev. Immunol.
16,
111-135[CrossRef][Medline]
[Order article via Infotrieve]
|
3.
|
Schonbeck, U.,
and Libby, P.
(2001)
Circ. Res.
89,
1092-1103[Abstract/Free Full Text]
|
4.
|
Lutgens, E.,
and Daemen, M. J.
(2002)
Trends Cardiovasc. Med.
12,
27-32[CrossRef][Medline]
[Order article via Infotrieve]
|
5.
|
Kluth, B.,
Hess, S.,
Engelmann, H.,
Schafnitzel, S.,
Riethmuller, G.,
and Feucht, H. E.
(1997)
Cancer Res.
57,
891-899[Abstract]
|
6.
|
Biancone, L.,
Cantaluppi, V.,
Boccellino, M.,
Del Sorbo, L.,
Russo, S.,
Albini, A.,
Stamenkovic, I.,
and Camussi, G.
(1999)
J. Immunol.
163,
6201-6208[Abstract/Free Full Text]
|
7.
|
Shu, H. B.,
Halpin, D. R.,
and Goeddel, D. V.
(1997)
Immunity
6,
751-763[Medline]
[Order article via Infotrieve]
|
8.
|
Reul, R. M.,
Fang, J. C.,
Denton, M. D.,
Geehan, C.,
Long, C.,
Mitchell, R. N.,
Ganz, P.,
and Briscoe, D. M.
(1997)
Transplantation
64,
1765-1774[Medline]
[Order article via Infotrieve]
|
9.
|
Karmann, K.,
Hughes, C. C.,
Schechner, J.,
Fanslow, W. C.,
and Pober, J. S.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
4342-4346[Abstract]
|
10.
|
Henn, V.,
Slupsky, J. R.,
Grafe, M.,
Anagnostopoulos, I.,
Forster, R.,
Muller-Berghaus, G.,
and Kroczek, R. A.
(1998)
Nature
391,
591-594[CrossRef][Medline]
[Order article via Infotrieve]
|
11.
|
Thienel, U.,
Loike, J.,
and Yellin, M. J.
(1999)
Cell. Immunol.
198,
87-95[CrossRef][Medline]
[Order article via Infotrieve]
|
12.
|
Slupsky, J. R.,
Kalbas, M.,
Willuweit, A.,
Henn, V.,
Kroczek, R. A.,
and Muller-Berghaus, G.
(1998)
Thromb. Haemost.
80,
1008-1014[Medline]
[Order article via Infotrieve]
|
13.
|
Dechanet, J.,
Grosset, C.,
Taupin, J. L.,
Merville, P.,
Banchereau, J.,
Ripoche, J.,
and Moreau, J. F.
(1997)
J. Immunol.
159,
5640-5647[Abstract]
|
14.
|
Schonbeck, U.,
Mach, F,
Bonnefoy, J. Y.,
Loppnow, H.,
Flad, H. D.,
and Libby, P.
(1997)
J. Biol. Chem.
272,
19569-19574[Abstract/Free Full Text]
|
15.
|
Mach, F.,
Schonbeck, U.,
Sukhova, G. K.,
Bourcier, T.,
Bonnefoy, J. Y.,
Pober, J. S.,
and Libby, P.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
1931-1936[Abstract/Free Full Text]
|
16.
|
Schonbeck, U.,
Sukhova, G. K.,
Shimizu, K.,
and Libby, P.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
7458-7463[Abstract/Free Full Text]
|
17.
|
Mach, F.,
Schonbeck, U.,
Sukhova, G. K.,
Atkinson, E.,
and Libby, P.
(1998)
Nature
394,
200-203[CrossRef][Medline]
[Order article via Infotrieve]
|
18.
|
Mach, F.,
Schonbeck, U.,
Fabunmi, R. P.,
Murphy, C.,
Atkinson, E.,
Bonnefoy, J. Y.,
Graber, P.,
and Libby, P.
(1999)
Am. J. Pathol.
154,
229-238[Abstract/Free Full Text]
|
19.
|
Melter, M.,
Reinders, M. E. J.,
Sho, M.,
Pal, S.,
Geehan, C.,
Denton, M. D.,
Mukhopadhyay, D.,
and Briscoe, D.
(2000)
Blood
96,
3801-3808[Abstract/Free Full Text]
|
20.
|
Foy, T. M.,
Aruffo, A.,
Bajorath, J.,
Buhlmann, J. E.,
and Noelle, R. J.
(1996)
Annu. Rev. Immunol.
14,
591-617[CrossRef][Medline]
[Order article via Infotrieve]
|
21.
|
Biancone, L.,
Cantaluppi, V.,
and Camussi, G.
(1999)
Int. J. Mol. Med.
3,
343-353[Medline]
[Order article via Infotrieve]
|
22.
|
Young, L. S.,
Eliopoulos, A. G.,
Gallagher, N. J.,
and Dawson, C. W.
(1998)
Immunol. Today
19,
502-506[CrossRef][Medline]
[Order article via Infotrieve]
|
23.
|
Arch, R. H.,
Gedrich, R. W.,
and Thompson, C. B.
(1998)
Genes Dev.
12,
2821-2830[Free Full Text]
|
24.
|
Pullen, S. S.,
Miller, H. G.,
Everdeen, D. S.,
Dang, T. T. A.,
Crute, J. J.,
and Kehry, M. R.
(1998)
Biochemistry
37,
11836-11845[CrossRef][Medline]
[Order article via Infotrieve]
|
25.
|
Hu, H. M.,
O'Rourke, K.,
Boguski, M. S.,
and Dixit, V. M.
(1994)
J. Biol. Chem.
269,
30069-30072[Abstract/Free Full Text]
|
26.
|
Cheng, G.,
Cleary, A. M.,
Ye, Z. S.,
Hong, D. I.,
Lederman, S.,
and Baltimore, D.
(1995)
Science
267,
1494-1498[Medline]
[Order article via Infotrieve]
|
27.
|
Ishida, T.,
Mizushima, S.,
Azuma, S.,
Kobayashi, N.,
Tojo, T.,
Suzuki, K.,
Aizawa, S.,
Watanabe, T.,
Mosialos, G.,
Kieff, E.,
Yamamoto, T.,
and Inoue, J.
(1996)
J. Biol. Chem.
271,
28745-28748[Abstract/Free Full Text]
|
28.
|
Werneburg, B. G.,
Zoog, S. J.,
Dang, T. T.,
Kehry, M. R.,
and Crute, J. J.
(2001)
J. Biol. Chem.
276,
43334-43342[Abstract/Free Full Text]
|
29.
|
Arron, J. R.,
Vologodskaia, M.,
Wong, B. R.,
Naramura, M.,
Kim, N.,
Gu, H.,
and Choi, Y.
(2001)
J. Biol. Chem.
276,
30011-30017[Abstract/Free Full Text]
|
30.
|
Shiojima, I.,
and Walsh, K.
(2002)
Circ. Res.
90,
1243-1250[Abstract/Free Full Text]
|
31.
|
Conaldi, P. G.,
Serra, C.,
Mossa, A.,
Falcone, V.,
Basolo, F.,
Camussi, G.,
Dolei, A.,
and Toniolo, A.
(1997)
J. Infect. Dis.
175,
693-696[Medline]
[Order article via Infotrieve]
|
32.
|
Kotamraju, S.,
Koronev, E. A.,
Joseph, J.,
and Kalyanaraman, B.
(2000)
J. Biol. Chem.
275,
33585-33592[Abstract/Free Full Text]
|
33.
|
Deregibus, M. C.,
Cantaluppi, V.,
Doublier, S.,
Brizzi, M. F.,
Deambrosis, I.,
Albini, A.,
and Camussi, G.
(2002)
J. Biol. Chem.
77,
25195-25202[CrossRef]
|
34.
|
Montesano, R.,
Soriano, J. V.,
Pepper, M. S.,
and Orci, L.
(1997)
J. Cell. Physiol.
173,
152-161[CrossRef][Medline]
[Order article via Infotrieve]
|
35.
|
Wong, B. R.,
Besser, D.,
Kim, N.,
Arron, J. R.,
Vologodskaia, M.,
Hanafusa, H.,
and Choi, Y.
(1999)
Mol. Cell
4,
1041-1049[Medline]
[Order article via Infotrieve]
|
36.
|
Cross, D. A. E.,
Alessi, D. R.,
Cohen, P.,
Andjelkovich, M.,
and Hemmings, B. A.
(1995)
Nature
378,
785-789[CrossRef][Medline]
[Order article via Infotrieve]
|
37.
|
Franke, T. F.,
Yang, S.,
Chan, T. O.,
Datta, K.,
Kazlauskas, A.,
Morrison, D. K.,
Kaplan, D. R.,
and Tsichlis, P. N.
(1995)
Cell
81,
727-736[Medline]
[Order article via Infotrieve]
|
38.
|
Bussolati, B.,
Russo, S.,
Deambrosis, I.,
Cantaluppi, V.,
Volpe, A.,
Ferrando, U.,
and Camussi, G.
(2002)
Int. J. Cancer
100,
654-661[CrossRef][Medline]
[Order article via Infotrieve]
|
39.
|
Talapatra, S.,
and Thompson, C. B.
(2001)
J. Pharmac. Exp. Ther.
298,
873-878[Abstract/Free Full Text]
|
40.
|
Gerber, H. P.,
Mc Murtrey, A.,
Kowalskj, J.,
Yan, M.,
Keyt, B. A.,
Dixit, V.,
and Ferrara, N.
(1998)
J. Biol. Chem.
273,
30336-30343[Abstract/Free Full Text]
|
41.
|
Weihua, W.,
Lee, W. L.,
Wu, Y. Y.,
Chen, D.,
Liu, T. J.,
Jang, A.,
Sharma, P. M.,
and Wang, P. H.
(2000)
J. Biol. Chem.
275,
40113-40119[Abstract/Free Full Text]
|
42.
|
Del Peso, L.,
Gonzales-Garcia, M.,
Page, C.,
Herrera, R.,
and Nunez, G.
(1997)
Science
278,
687-689[Abstract/Free Full Text]
|
43.
|
Franke, T. F.,
Kaplan, D. R.,
and Cantley, L. C.
(1997)
Cell
88,
435-437[Medline]
[Order article via Infotrieve]
|
44.
|
Alessi, D. R.,
James, S. R.,
Downes, C. P.,
Holmes, A. B.,
Gaffney, P. R.,
Reese, C. B.,
and Cohen, P.
(1997)
Curr. Biol.
7,
261-269[Medline]
[Order article via Infotrieve]
|
45.
|
Zhang, L.,
Zhou, W.,
Velculescu, V. E.,
Kern, S. E.,
Hruban, R. H.,
Hamilton, S. R.,
Vogelstein, B.,
and Kinzler, K. W.
(1997)
Science
276,
1268-1272[Abstract/Free Full Text]
|
46.
|
Zhou, H.,
Xin-Ming, L.,
Meinkoth, J.,
and Pittman, R. N.
(2000)
J. Cell Biol.
151,
483-494[Abstract/Free Full Text]
|
47.
|
Urbich, C.,
Mallat, Z.,
Tedgui, A.,
Clauss, M.,
Zeiher, A. M.,
and Dimmeler, S.
(2001)
J. Clin. Invest.
108,
1451-1458[Abstract/Free Full Text]
|
48.
|
Malinin, N. L.,
Boldin, M. P.,
Kovalenko, A. V.,
and Wallach, D.
(1997)
Nature
385,
540-544[CrossRef][Medline]
[Order article via Infotrieve]
|
49.
|
Takeuchi, M.,
Rothe, M.,
and Goeddel, D. V.
(1996)
J. Biol. Chem.
271,
19935-19942[Abstract/Free Full Text]
|
50.
|
McCarthy, J. V.,
Ni, J.,
and Dixit, V. M.
(1998)
J. Biol. Chem.
273,
16968-16975[Abstract/Free Full Text]
|
51.
|
Yuasa, T.,
Ohno, S.,
Kehrl, J. H.,
and Kyriakis, J. M.
(1998)
J. Biol. Chem.
273,
22681-22692[Abstract/Free Full Text]
|
52.
|
Nishitoh, H.,
Saitoh, M.,
Mochida, Y.,
Takeda, K.,
Nakano, H.,
Rothe, M.,
Miyazono, K.,
and Ichijo, H.
(1998)
Mol. Cell
2,
389-395[Medline]
[Order article via Infotrieve]
|
Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.